SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutic...
Saved in:
Main Authors | , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
09.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. |
---|---|
AbstractList | The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. |
Author | LUO, Hong HAN, Yongxin LIU, Xijie LIU, Mei LIU, Bo HU, Yuandong XU, Hongjiang CHEN, Kuncheng PENG, Yong WANG, Shanchun WANG, Shulong |
Author_xml | – fullname: PENG, Yong – fullname: LIU, Xijie – fullname: LIU, Mei – fullname: HAN, Yongxin – fullname: WANG, Shulong – fullname: HU, Yuandong – fullname: CHEN, Kuncheng – fullname: LIU, Bo – fullname: WANG, Shanchun – fullname: XU, Hongjiang – fullname: LUO, Hong |
BookMark | eNqNyr0OgjAUQOEOOvj3DvcBdDAQnEt7kRuhbdrbwYkQU10MkOD7RwYfwOk7w9mK1TAOaSNeIZaBiSOjBnf33jZ2gVrSZBCUvgGZmkpi64_gaulbqTAyKdmAsq2zgZisWdqwJEPmCkG2CNJoiAGBa_Roq71YP_v3nA4_dwIqZFWf0jR2aZ76RxrSp0OX5VleXIrynP2xfAFPYjdj |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | SUBSTITUIERTE PYRROLOPYRIMIDIN-CDK-HEMMER, PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT UND VERWENDUNG DAVON INHIBITEUR DE CDK PYRROLOPYRIMIDINE SUBSTITUÉE, COMPOSITION PHARMACEUTIQUE LE COMPRENANT ET SON UTILISATION |
ExternalDocumentID | EP3434676B1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_EP3434676B13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:59:23 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French German |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_EP3434676B13 |
Notes | Application Number: EP20170769492 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220309&DB=EPODOC&CC=EP&NR=3434676B1 |
ParticipantIDs | epo_espacenet_EP3434676B1 |
PublicationCentury | 2000 |
PublicationDate | 20220309 |
PublicationDateYYYYMMDD | 2022-03-09 |
PublicationDate_xml | – month: 03 year: 2022 text: 20220309 day: 09 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | Lianyungang Runzhong Pharmaceutical Co., Ltd Centaurus BioPharma Co., Ltd Chia Tai Tianqing Pharmaceutical Group Co., Ltd |
RelatedCompanies_xml | – name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd – name: Lianyungang Runzhong Pharmaceutical Co., Ltd – name: Centaurus BioPharma Co., Ltd |
Score | 3.392388 |
Snippet | The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220309&DB=EPODOC&locale=&CC=EP&NR=3434676B1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT8IwFG4IGvWmqBF_pQezk0QZ2xgHYrauc1XXLltn8ES2MQwXIDLjv-_rAuhFT31pk5f2Je97fa_tV4RuJoWpWE-mkJZAbmIUZdHJ7azbybPSyKZ60e_mqt4RcitIjaeROWqg2eYtTM0T-lWTI4JHFeDvVY3Xy58illffrVzd5TPoWjz4cuhp6-xY19WJgea5QxoJTxCNEJA0HgNY9wASLBcSpR21i1Y0-_TVVY9Slr8jin-IdiNQNq-OUKOct9A-2Xy81kJ74fq8G8S1662O0XuSuolkMgWowdFbHIsXAQ1gj8c4xcR7xowHzGVSxLc4Cpw4dAhNpeI7wESEkUiYKkeBzKXDOOOPOHFCih3u4TShWAY0psI_QdinkgQdmPF4a50xjbZr652i5nwxL88QtgrTnuqG3b23B8bAsvPCzsp-1jcngLR2z2qj9p9qzv8Zu0AHysz1LazBJWpWH5_lFYTlKr-uDfoNqM-Kdg |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEG8IGvFNUSN-9sHsSaKMffFAzNZ1rsK6ZesMPpFtDMPLIDLjv-9tAfRFn3ppk0t7yf0uv2vvitDdLFOrridzoCXATZQsz7qpkfS6aZIryVzO9F5a5Ts8rrmx8jJRJw202NbC1H1Cv-rmiOBRGfh7WeP16ieJZddvK9cP6QKmlk-OGNrShh3LcnVjINnWkAa-7ROJEJAkHgJY9wESNAuI0p4OjLBmSq9WVZSy-h1RnCO0H4CyojxGjbxooxbZfrzWRgfe5r4bxI3rrU_QexRbkWAiBqjBwVsY-mMfBsAem3GKiT3CjLvMYsIP73HgmqFnEhqLqt8BJr4X-BGr0lEgc2EyzvgzjkyPYpPbOI4oFi4Nqe-cIuxQQdwu7Hi6s86UBruz9c9Qs1gW-TnCWqYac1kxeo_GQBloRpoZSa4nujoDpDX6Wgd1_lRz8c_aLWq5whtPx4yPLtFhZfL6RdbgCjXLj8_8GkJ0md7Uxv0GR4SNYA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=SUBSTITUTED+PYRROLOPYRIMIDINE+CDK+INHIBITOR%2C+PHARMACEUTICAL+COMPOSITION+CONTAINING+SAME+AND+USE+THEREOF&rft.inventor=PENG%2C+Yong&rft.inventor=LIU%2C+Xijie&rft.inventor=LIU%2C+Mei&rft.inventor=HAN%2C+Yongxin&rft.inventor=WANG%2C+Shulong&rft.inventor=HU%2C+Yuandong&rft.inventor=CHEN%2C+Kuncheng&rft.inventor=LIU%2C+Bo&rft.inventor=WANG%2C+Shanchun&rft.inventor=XU%2C+Hongjiang&rft.inventor=LUO%2C+Hong&rft.date=2022-03-09&rft.externalDBID=B1&rft.externalDocID=EP3434676B1 |